Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study

被引:334
作者
Faivre, J
Dancourt, V
Lejeune, C
Tazi, MA
Lamour, J
Gerard, D
Dassonville, F
Bonithon-Kopp, C
机构
[1] Fac Med, Registre Canc Digestifs, INSERM, EPI 0106, F-21079 Dijon, France
[2] Fac Med, Burgundy Canc Registry, INSERM, EPI 0106, F-21079 Dijon, France
关键词
D O I
10.1053/j.gastro.2004.02.018
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Several randomized population-based studies have shown that screening for colorectal cancer (CRC) by fecal occult blood tests (FOBTs) can reduce CRC mortality. The aim of this French population-based study was to assess whether a similar benefit could be obtained in countries characterized by high performances in the diagnosis and management of CRC. Methods: Small-sized geographic areas, including 91,199 individuals aged 45-74 years, were allocated to either FOBT screening or no screening. Six screening rounds were performed. The FOBT was performed without diet restriction and was sent to a central analysis center and processed without rehydration. Screening group participants who had a positive test result were offered a full colonoscopy. The entire population was followed up for 11 years after study entry. Results: Acceptability of the test was 52.8% at the first screening round and varied between 53.8% and 58.3% in the successive rounds. Positivity rates were 2.1% initially and 1.4% on average in the successive rounds. CRC mortality was significantly lower in the screening population compared with the control population (mortality ratio, 0.84; 95% confidence interval, 0.71-0.99). The reduction in CRC mortality was more pronounced in those who participated at least once (mortality ratio, 0.67; 95% confidence interval, 0.56-0.81). Conclusions: Our findings, together with the results of other trials, suggest that biennial screening by FOBTs can reduce CRC mortality regardless of the quality of the health system and support attempts to introduce large-scale screening programs into the general population.
引用
收藏
页码:1674 / 1680
页数:7
相关论文
共 20 条
[1]   Understanding variations in survival for colorectal cancer in Europe: a EUROCARE high resolution study [J].
Gatta, G ;
Capocaccia, R ;
Sant, M ;
Bell, CMJ ;
Coebergh, JWW ;
Damhuis, RAM ;
Faivre, J ;
Martinez-Garcia, C ;
Pawlega, J ;
de Leon, MP ;
Pottier, D ;
Raverdy, N ;
Williams, EMI ;
Berrino, F .
GUT, 2000, 47 (04) :533-538
[2]   Survival of colorectal cancer patients in Europe during the period 1978-1989 [J].
Gatta, G ;
Faivre, J ;
Capocaccia, R ;
de Leon, AP .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (14) :2176-2183
[3]   Analysis of screening data: Colorectal cancer [J].
Gyrd-Hansen, D ;
Sogaard, J ;
Kronborg, O .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1997, 26 (06) :1172-1181
[4]   Randomised controlled trial of faecal-occult-blood screening for colorectal cancer [J].
Hardcastle, JD ;
Chamberlain, JO ;
Robinson, MHE ;
Moss, SM ;
Amar, SS ;
Balfour, TW ;
James, PD ;
Mangham, CM .
LANCET, 1996, 348 (9040) :1472-1477
[5]   A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds [J].
Jorgensen, OD ;
Kronborg, O ;
Fenger, C .
GUT, 2002, 50 (01) :29-32
[6]   Estimation of screening test (Hemoccult®) sensitivity in colorectal cancer mass screening [J].
Jouve, JL ;
Remontet, L ;
Dancourt, V ;
Lejeune, C ;
Benhamiche, AM ;
Faivre, J ;
Esteve, J .
BRITISH JOURNAL OF CANCER, 2001, 84 (11) :1477-1481
[7]  
KEWENTER J, 1988, CANCER, V62, P645, DOI 10.1002/1097-0142(19880801)62:3<645::AID-CNCR2820620333>3.0.CO
[8]  
2-#
[9]   Randomised study of screening for colorectal cancer with faecal-occult-blood test [J].
Kronborg, O ;
Fenger, C ;
Olsen, J ;
Jorgensen, OD ;
Sondergaard, O .
LANCET, 1996, 348 (9040) :1467-1471
[10]  
Launoy G, 1997, INT J CANCER, V73, P220, DOI 10.1002/(SICI)1097-0215(19971009)73:2<220::AID-IJC10>3.0.CO